SCHEMBL9966941

SCHEMBL9966941

CC(F)(F)c1ccc(Cl)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 4/20 0.42
KCNQ2 O43526 4/20 0.42
KCNQ1 P51787 4/20 0.42
KCNE1 P15382 3/20 0.42
GRM4 Q14833 1/20 0.40
ALDH1A1 P00352 1/20 0.37
PIK3CD O00329 1/20 0.36
NAPRT Q6XQN6 1/20 0.36
TRPA1 O75762 1/20 0.36
SCN5A Q14524 1/20 0.36
DYRK1A Q13627 1/20 0.36
DYRK2 Q92630 1/20 0.36
POLB P06746 1/20 0.35
CYP19A1 P11511 3/20 0.35
BACE1 P56817 1/20 0.35
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
CYP2A6 P11509 1/20 0.34
DGAT1 O75907 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29879160 1.00 KCNQ3 (0.42) KCNQ3KCNQ2KCNQ1KCNE1GRM4
SCHEMBL25326819 0.83 KCNQ3 (0.41) KCNQ3KCNQ2KCNQ1KCNE1GRM4
SCHEMBL29364836 0.82 KCNQ3 (0.53) KCNQ3KCNQ2KCNQ1KCNE1GRM4
SCHEMBL29909266 0.82 POLB (0.40) KCNQ3KCNQ2KCNQ1KCNE1ALDH1A1
SCHEMBL41029 0.82 KCNQ3 (0.53) KCNQ3KCNQ2KCNQ1KCNE1GRM4
SCHEMBL77078 0.82 POLB (0.40) KCNQ3KCNQ2KCNQ1KCNE1ALDH1A1
SCHEMBL10951721 0.81 KCNQ3 (0.41) KCNQ3KCNQ2KCNQ1KCNE1GRM4
SCHEMBL31000265 0.80 GCK (0.46) KCNQ3KCNQ2KCNQ1KCNE1GRM4
SCHEMBL31000262 0.80 GCK (0.46) KCNQ3KCNQ2KCNQ1KCNE1GRM4
SCHEMBL18053748 0.80 GCK (0.46) KCNQ3KCNQ2KCNQ1KCNE1GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 EP disclosed
EP-4568959-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-06-18 EP disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 EP disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US disclosed
WO-2024033389-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-02-15 WO disclosed
EP-4308230-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 EP disclosed
CN-117355521-A Heteroaryl inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-05 CN disclosed
US-20150359223-A1 COMPOSITION AND METHOD FOR CONTROLLING PESTS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-12-17 US disclosed
US-9120823-B2 Fused heterocyclic compound and use thereof for pest control SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-09-01 US disclosed
US-20150197532-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-07-16 US disclosed
US-9018134-B2 Fused heterocyclic compound and use thereof for pest control SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-04-28 US disclosed
US-9006450-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-14 US disclosed
US-9006450-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-14 US disclosed
US-20140194290-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-07-10 US disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
WO-2012001107-A1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 KCNQ3 1143/4885KCNQ2 1067/4885KCNQ1 1092/4885
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF P2RX5, P2RX3, ABCG2 KCNQ3 115/4885KCNQ2 98/4885KCNQ1 104/4885
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP KCNQ3 1261/4885KCNQ2 1921/4885KCNQ1 1803/4885
US-20140194290-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL NR0B1, NR4A1, NR2C2 KCNQ3 3759/4885KCNQ2 3648/4885KCNQ1 3715/4885
US-20150359223-A1 COMPOSITION AND METHOD FOR CONTROLLING PESTS PNPO, NAMPT, NNT KCNQ3 311/4885KCNQ2 157/4885KCNQ1 148/4885
US-20150197532-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL NR0B1, NR4A1, NR2C2 KCNQ3 3759/4885KCNQ2 3648/4885KCNQ1 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.